Axogen Q3 revenue $60.1M (+23.5% YoY); raises FY revenue guidance to at least $222.8M

Axogen, Inc.

2025-Q3 EPS reported -$0.06 revenue$165,304,000

Net income of $0.7M ($0.01 EPS) vs net loss of $1.9M in Q3 2024; adjusted EPS $0.12 vs $0.07.
Gross margin improved to 76.6% from 74.9% YoY; adjusted EBITDA $9.2M vs $6.5M.
Raised full-year revenue guidance to at least $222.8M (≥19% growth); gross margin reaffirmed 73-75%.
FDA PDUFA for Avance Nerve Graft BLA extended to Dec 5, 2025; AAHS and ASRM issued position statements recognizing nerve allografts.
Added 18.1M covered lives in 2025; commercial payer coverage now over 64%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.